Novartis boosts involvement in anti-Covid treatment
The biotech company and the pharmaceutical giant want to develop and market a drug with a unique approach for the prevention and treatment of Covid-19.
Keystone/Alexandra Wey
Swiss pharmaceutical company Novartis says it has signed a deal with biotech firm Molecular Partners to develop, manufacture and commercialise an anti-Covid-19 treatment drug.
The Basel-based company said the option and licence agreement was aimed at boosting a programme consisting of two antiviral therapeutic candidates, MP0420 and MP0423.
“It is clear that this pandemic calls for not just scientific solutions, but also for collaboration between companies to provide treatments in an area of high unmet need,” Novartis said in a statement publishedExternal link on Wednesday.
Molecular Partners will be responsible for the conduct of phase 1 and 2 trials.
Under the terms of the agreement, Molecular Partners will receive an initial payment of CHF60 million ($66.1 million). If Novartis takes up the option to both drugs, it will pay another CHF150 million to the biotech company.
In August, the Swiss government signed an agreement with Molecular Partners for priority access to a drug being developed to treat those severely ill with Covid-19.
It gives Switzerland access to the first 200,000 doses of the medicine, as well as up to three million further doses when requested.
Doctors Without Borders demands Swiss Gaza clarification
This content was published on
The NGO Doctors Without Borders (MSF) has challenged Swiss foreign minister Ignazio Cassis to explain his controversial Gaza statements.
Data centres use four times more electricity than average
This content was published on
The power consumption of data centres, used in particular for AI, is four times higher than average, warns the International Telecommunication Union.
One in five bee colonies failed to survive Swiss winter
This content was published on
Almost a fifth of bee colonies in Switzerland failed to survive the winter. Losses have been greater than in previous years.
Switzerland condemns deadly attack on UN convoy in Sudan
This content was published on
Switzerland has strongly condemned the deadly attack on a United Nations humanitarian convoy in Sudan. Five people were killed, wrote the Federal Department of Foreign Affairs (FDFA) on Platform X.
Most over-65s in Switzerland regularly use the internet
This content was published on
The digital divide is narrowing faster than expected in Switzerland. A study published on Wednesday reveals that nine out of ten over-65s use the internet.
Will Swiss president be forbidden from speaking English to counterparts?
This content was published on
Switzerland's president, Karin Keller-Sutter, should use one of the country's four national languages when communicating with international organisations, and not English, according to a motion that passed on Wednesday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche bids to co-develop potential oral Covid-19 treatment
This content was published on
The Basel-based company has partnered with Atea Pharmaceuticals to develop, manufacture and distribute the latter’s oral anti-Covid-19 treatment.
Switzerland fast-tracks antiviral medication against Covid-19
This content was published on
Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval of the drug, which is produced under the brand name Veklury by US biopharmaceutical company Gilead Sciences. The application for its extended use was only received on Monday. It can now be used for a limited period of time to…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.